"Competitive reasons..." This is the 'why' LABS did issue ap.r. corresponding to the AVCN release referencing the expanded manufacturing agreement. Had LABS issued a corresponding press release, from their end they would have to provide DETAILS as to what the 'expanded strategic manufacturing agreement' contains within it. So instead, 'for competitive reasons' they stayed silent and did not issue a corresponding p.r.
I personally believe this has something to do with the 'new drug monograph' that LABS made mention of that they are waiting for from the FDA.
A 'new drug monograph', even the mention of it by LABS simply means they have a new drug within the FDA and they are going through the approval process for it. A focused review by the FDA takes no longer than 6 months. Standard review takes 10 months.
AVCN's expanded strategic manufacturing agreement p.r. to me at least is telling me they have their site approval by the FDA as a pharmaceutical level producer and are (both LABS and AVCN) waiting for the FDA new drug approval.
The CEO of LABS clearly stated they are waiting for a drug monograph from the FDA.
And, as said by the CEO of LABS....."if only one of these drugs are approved it will change the face of the company"
We ARE at that cross roads now.
So anyone playing the day trader and jumping in out with a short position, imho, could have their ballz shoved down their throat...especially if it's a mid day halt trade BECAUSE we don't know what time of day the FDA will inform LABS of their new drug monograph.
This stock price WILL be going up because the Drug Master File that LABS submitted to the FDA was approved a long time ago and it is that DMF that will be referenced in the new drug monograph. Trunerox?....seems to be the logical candidate.